Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/1999

01-02-1999

Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812)

Authors: Kendra D. Tutsch, Rhoda Z. Arzoomanian, Dona Alberti, Mary B. Tombes, Christine Feierabend, H. Ian Robins, David R. Spriggs, George Wilding

Published in: Investigational New Drugs | Issue 1/1999

Login to get access
Metadata
Title
Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812)
Authors
Kendra D. Tutsch
Rhoda Z. Arzoomanian
Dona Alberti
Mary B. Tombes
Christine Feierabend
H. Ian Robins
David R. Spriggs
George Wilding
Publication date
01-02-1999
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 1/1999
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1006223100561

Other articles of this Issue 1/1999

Investigational New Drugs 1/1999 Go to the issue

OriginalPaper

Activity and DNA binding of new organoamidoplatinum (II) complexes

OriginalPaper

Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study

OriginalPaper

A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer

OriginalPaper

Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study

OriginalPaper

Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin

OriginalPaper

A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits